Mon, 20 Jan 2025, 09:59 pm
Health

Covaxin booster dose trial shows ‘long-term safety’: Bharat Biotech

Hyderabad-based vaccine manufacturer Bharat Biotech said on Saturday (January 8) that its trials for Covaxin booster dose have shown ‘long-term safety’ with no serious adverse events. Bharat Biotech said that

read more

WHO recommends 14-day quarantine for COVID-19 patients

Although most people recover from COVID-19 within five to seven days of the onset of symptoms, the World Health Organization (WHO) still recommends a 14-day quarantine, an official from the

read more

US authorizes Pfizer booster for kids as young as 12

US health authorities on Monday approved Pfizer’s Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six

read more

Hospitalisation risk from Omicron nearly one-third of Delta: Study

The risk of hospitalisation with the Omicron variant of coronavirus is about one-third that of the Delta variant, according to British analysis of more than a million cases of both

read more

Covid-19: WHO chief optimistic disease will be beaten in 2022

The World Health Organization (WHO) chief says he is optimistic that the coronavirus pandemic will be defeated in 2022, provided countries work together to contain its spread. Dr Tedros Adhanom

read more

Rapid Covid tests not as accurate with Omicron: US regulator

Rapid Covid home tests are more likely to give a false negative with the heavily-mutated Omicron variant compared to earlier strains, the US Food and Drug Administration (FDA) said Tuesday.

read more

Covid: Australian trial tests blood thinner as nasal spray

Australian researchers are conducting a trial to see whether squirting a blood thinner into the nose could offer protection against Covid. The nasal spray uses the cheap drug heparin in

read more

New drug could treat COVID-19 pneumonia: Lancet

A newly identified drug may be used to effectively treat some patients hospitalised with COVID-19 pneumonia, according to a study published in The Lancet Respiratory Medicine journal, PTI reported. The

read more

J&J shot loses antibody protection against Omicron in study

Johnson & Johnson’s vaccine produced virtually no antibody protection against the omicron coronavirus variant in a laboratory experiment, underlining the new strain’s ability to get around one pillar of the

read more

Omicron Covid-19 variant more transmissible, reduces vaccine efficiency: WHO

The World Health Organization (WHO) on Sunday warned that the newer Omicron variant (B.1.1.529) of SARS-CoV-2 is more transmissible than the Delta strain and reduces vaccine efficiency but caused less

read more

© All rights reserved © 2019 WeeklyBangladeshNY.Net
Theme Dwonload From ThemesBazar.Com